Research Summary

Dr. Rebecca Olin is a hematologist who specializes in bone marrow transplantation in adults. Her expertise encompasses treating acute leukemia, myelodysplastic and myeloproliferative disorders (conditions in which the bone marrow makes too many white blood cells) and aplastic anemia (a condition in which the body doesn’t make enough new blood cells).

In her research, Olin has a particular interest in studying how best to treat blood cancers in older patients, some of whom may require a bone marrow transplant.

Olin earned her medical degree from the Perelman School of Medicine at the University of Pennsylvania and was elected to the Alpha Omega Alpha Honor Medical Society. She completed a residency in internal medicine as well as a fellowship in hematology and oncology at the Hospital of the University of Pennsylvania, serving as chief fellow for one year. She also has a master's degree in clinical epidemiology, with a focus on medical decision making, from the University of Pennsylvania.


Amherst College, Amherst, MA, B.A., 1999, Biology
University of Pennsylvania School of Medicine, M.D., 2003
University of Pennsylvania, M.S., 2009, Clinical Epidemiology

Honors & Awards

  • 1999
    Phi Beta Kappa, Amherst College
  • 2002
    Alpha Omega Alpha, early induction, University of Pennsylvania
  • 2002
    Botelho Prize for Excellence in Basic Science
  • 2003
    Dr. Spencer Morris Prize
  • 2005
    American Society of Hematology Trainee Award
  • 2008
    American Society of Hematology Travel Award
  • 2018
    Heme/BMT Value Improvement Program's "Great Save Award," University of California San Francisco
  • 2018
    Health Value Improvement Program's "Best Partnerships Across Initiatives," University of California San Francisco

Selected Publications

  1. Tsang M, Bischoff K, Schoenbeck KL, Berry K, O'Riordan D, Fakhri B, Wong SW, Shah N, Olin R, Andreadis C, Vieaux J, Cohen E, Lopez NS, Mannis GN, Rabow M. Value of embedded palliative care: outpatient palliative care and health care utilization for patients with hematologic malignancies. Blood Adv. 2023 Jul 11; 7(13):3146-3149.  View on PubMed
  2. Jeng MY, Kong D, Rajalingam R, Lin RJ, Olin RL. Lack of disease control remains a major barrier to transplant for older patients with AML. Bone Marrow Transplant. 2023 Jun 23.  View on PubMed
  3. Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 06 13; 7(11):2360-2363.  View on PubMed
  4. E. A. Brem, H. Li, A. W. Beaven, P. Caimi, L. Cerchietti, R. L. Olin, N. L. Henry, H. Dilon, R. F. Little, M. L. Leblanc, B. Kahl, J. P. Leonard, J. W. Friedberg, S. M. Smith. PHASE II/III STUDY OF R-MINICHOP ± ORAL AZACITIDINE IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH DIFFUSE LARGE B CELL AND RELATED LYMPHOMAS. Hematological Oncology. 2023 Jun 9; 41(S2):848-849.  View on PubMed
  5. Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 05; 21(5):503-513.  View on PubMed
  6. Wall SA, Olin R, Bhatt V, Chhabra S, Munshi P, Hacker E, Hashmi S, Hassel H, Howard D, Jayani R, Lin R, McCurdy S, Mishra A, Murthy H, Popat U, Wood W, Rosko AE, Artz A. The Transplantation Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Transplantation Patients. Transplant Cell Ther. 2023 May 01.  View on PubMed
  7. Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Redner RL, Al-Mansour Z, Cogle CR, Swords RT, Collins RH, Vergilio JA, Heerema NA, Rosenberg L, Yocum AO, Marcus S, Chen T, Druggan F, Stefanos M, Gana TJ, Shoben AB, Druker BJ, Burd A, Byrd JC, Levine RL, Boyiadzis MM. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. 2023 08 01; 129(15):2308-2320.  View on PubMed
  8. Reyes KR, Huang CY, Lo M, Arora S, Chung A, Wong SW, Wolf J, Olin RL, Martin T, Shah N, Banerjee R. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. Transplant Cell Ther. 2023 06; 29(6):350-355.  View on PubMed
  9. Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023 03 16; 141(11):1265-1276.  View on PubMed
  10. Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578.  View on PubMed
  11. Andrew H. Tam, Aaron C. Logan, Angela J. Choi, Richard Fong, Lloyd E. Damon, Rebecca L. Olin, Neil Dunavin, Peter H. Sayre, Karin L. Gaensler, Catherine Smith, Lily Yan. Improved Gvhd and Relapse Free Survival Outcomes in Older Acute Leukemia Patients Receiving Young Haploidentical Donor Vs Older Matched Sibling Donor Reduced Intensity Conditioning Hematopoietic Cell Transplants. Blood. 2022 Nov 15; 140(Supplement 1):4895-4896.  View on PubMed
  12. Ashley E. Rosko, Carolyn J. Presley, Grant R. Williams, Rebecca L. Olin. Cancer and Aging. . 2022 Oct 21; 1-8.  View on PubMed
  13. Pérez-Pinzón J, Olin RL, Banerjee R. Severe electrolyte derangements from lysozymuria in acute myeloid leukemia. EJHaem. 2022 Aug; 3(3):1018-1020.  View on PubMed
  14. Kennedy VE, Huang CY, Kaplan LD, Andreadis C, Ai WZ, Olin RL. Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma. J Geriatr Oncol. 2022 06; 13(5):644-647.  View on PubMed
  15. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther. 2022 06; 28(6):309.e1-309.e9.  View on PubMed
  16. McCurdy SR, Olin RL. Transplantation for Older Adults-More Questions than Answers. Transplant Cell Ther. 2021 12; 27(12):955-956.  View on PubMed
  17. Elizabeth A Brem, Hongli Li, Anne W. Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh, Rebecca L. Olin, Norah Lynn Henry, Hildy Dilon, Richard F. Little, Cara Laubach, Michael L. Leblanc, Jonathan W. Friedberg, Sonali M. Smith. S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements. Blood. 2021 Nov 5; 138(Supplement 1):3565-3565.  View on PubMed
  18. Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, Henry NL, Dillon H, Little RF, Laubach C, LeBlanc M, Friedberg JW, Smith SM. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol. 2022 03; 13(2):258-264.  View on PubMed
  19. Kennedy VE, Olin RL. Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care. Lancet Haematol. 2021 Nov; 8(11):e853-e861.  View on PubMed
  20. Jayani RV, Olin RL. Physically "fit" for allogeneic stem cell transplant? Bone Marrow Transplant. 2021 11; 56(11):2628-2629.  View on PubMed

Go to UCSF Profiles, powered by CTSI